Ajankohtaista IMI-ohjelmasta

Transkriptio

1 Ajankohtaista IMI-ohjelmasta Katriina Kippo, Tekes 7.puiteohjelman viimeisten hakujen infopäivä Yhteiset teknologia-aloitteet DM Copyright Tekes

2 A Public Private Partnership 1 billion* 1 billion * Research performed by EFPIA member companies IMI Research funding for = in kind contribution IMI Research Projects Academia, SMEs, patients organisations, Regulatory Authorities, etc. Copyright Tekes

3 The Research Agenda Identified pre-competitive bottlenecks in R&D process Proposed recommendations to address these bottlenecks Proposed a new model of Public-Private collaboration to implement recommendations

4 The Four Pillars of the Innovative Medicines Initiative

5 The Revised Agenda 2011: Key Areas Science Communication Tools and Techniques Patients IMI ACTIVITIES Development in Regulatory Framework Strategies in R&D Diseases Drug Efficacy Knowledge Management

6 Key Concepts Non-competitive research for EFPIA companies Competitive calls for IMI beneficiaries Open collaboration in public-private consortia

7 A typical IMI consortium Private Investment in kind ( 1 billion) Pharma 1 Pharma 2 Pharma 3 EFPIA Pharma 4 Pharma 5 Pharma 6 EU Public Funding cash ( 1 billion) ACADEMIA HOSPITALS PATIENTS ORGANISATIONS SMALL AND MEDIUM-SIZED ENTERPRISES REGULATORS

8 KEY FIGURES OF FIRST CALLS FOR PROPOSALS

9 Overview of IMI projects * Small and medium-sized enterprises

10 Successful Applicants Interested in patient-centric biomedical/pharmaceutical research Open to collaboration with large pharmaceutical companies

11 Geographic distribution of IMI JU funding to academic beneficiaries EUR

12 Small and medium-sized enterprises in IMI projects 56 SMEs (62 teams) involved in 1 st /2 nd /3 rd Call projects (+ 30 SMEs in 4 th Call 1 st ranked EoIs) 13% of IMI beneficiaries are SMEs SMEs receive 13% of IMI funding Type of SME IMI Funding Number of SMEs Biotech IT/Data Management Project Management Grand Total

13 First performance indicators ( )

14 Meneillään IMI:n 6. ja 7. haku 6 th Call: Combating Antibiotic Resistance: NewDrugs4BadBugs (ND4BB) Kaksivaiheinen haku, joka keskittyy bakteereiden antibioottivastustuskyvyn ongelmien ratkaisemiseen sekä uusien antimikrobilääkkeiden kliinisen vaiheen tutkimukseen. Toisen vaiheen haku päättyy Two topics of the 7 th Call: 1) Developing a framework for rapid assessment of vaccination benefit/risk in Europe 2) Incorporating real-life clinical data into drug development DM Copyright Tekes

15 7. Haun aihealueet Developing a framework for rapid assessment of vaccination benefit/risk in Europe This proposal is a new topic for 5 years project under the European Medical Information Framework (EMIF) project of patient-level data to support a wide range of medical research launced during the 4th Call of IMI in 2011 Incorporating real-life clinical data into drug development The aim is to create the decision-making framework for Pharma R&D for the systemic identification and assessment of different development strategies The research focus will be on disease areas where value is most likely to be delivered to patients and health care systems (e.g. diabetes, CVD, respiratory, oncology and neurology ) Kaksivaiheinen haku avattiin ja ensimmäinen vaihe sulkeutuu haun suuntaa-antava kokonaisbudjetti on 26 M DM Copyright Tekes

16 Mitä hakuja on suunnitteilla? Call 8: Topics are under the programme Combating Antibiotic Resistance: NewDrugForBadBugs Topic 1C (work packages, WPs 6 and 7) of Topic 1: Innovative Trial Design & Clinical Development An indicative description of topic 1C is included in the 6 th Call text WP 6: Conduct of Clinical Trials supporting the development of MEDI4893, a monoclonal antibody targeting S. aureus alpha toxin WP 7: Conduct of Clinical Trials supporting the development of AZD9773, a polyclonal ovine FaB fragment directed at tumor necrosis factor alpha (TNFα) for the treatment of the severe sepsis, including septic shock Haku avattaneen syyskuussa 2012 tai myöhemmin syksyllä DM Copyright Tekes

17 Mitä hakuja on suunnitteilla? 9. hakukierroksen alustavat teemat Development of drug-drug combinations Developing an aetiological based taxonomy of human disease Leveraging emerging technology for pharmacovigilance European induced pluripotent stem cell bank Discovery and development of new drugs combating Gram negative infections (Topic 3 of the programme Combating Antibiotic Resistance: NewDrugForBadBugs) Haku avattaneen marraskuussa Lisätiedot kunkin teeman sisällöstä web-linkeissä: DM Copyright Tekes

18 Horisontti 2020 ja IMI IMI perustettiin annetulla Neuvoston säädöksellä 73/2008. Perustuen IMI:n menestykseen Euroopan Komissio tutkii, minkälainen julkisen ja yksityisen sektorin yhteistyömuoto (PPP) olisi käynnistettävissä terveyden tukimuksen alueella Horisontti 2020-erityisohjelmassa. Sitä varten Komissio on avannut julkisen konsultaation (Plans for a public-private partnership in life sciences research and innovation under Horizon 2020). Siinä halutaan palautetta niin IMI:stä kuin innovatiivisesta terveystutkimuksesta sekä ideoita ja näkökulmia niihin liittyvistä tarvittavista tutkimuskohteista. Konsultaatio on avoinna Lisätietoja saa web-linkistä: Copyright Tekes

19 Tulevia tapahtumia IMI-yhteisyritys järjestää symposiumin aiheesta The Innovative Medicines Initiative Putting Policy into Practice Kyproksella, Larnakassa Lisätietoja IMI:n kotisivuilta: DM Copyright Tekes

20 Keep up to date Webinar: March 2012 Visit Sign up to the IMI Newsletter Follow us on Join the Innovative Medicines Initiative group on LinkedIn Questions? us:

21 Find project partners IMI Partner Search Tool: IMI States Representatives Group (SRG) member: Health National Contact Point (NCP): cordis.europa.eu/fp7/health/ncp_en.html

22 Partner Search Tool 22

23 Kiitos! IMI-SRG Representative of Finland